No abstract

Silica-based superhydrophobic coatings were produced on glass substrate by dip-coating process. Colloidal solutions containing nanoparticles of silica synthesized via seed growth method (single-and dual-sized particles) and dispersed in three different solvents, ethanol, silica sol and acidic silica sol, were used. Coatings with dual-sized particles in ethanol showed superhydrophobicity with a water contact angle of 155°. The coating adhesion was improved with the use of acidic silica sol as solvent. Coatings prepared from colloidal solution containing 30 wt.% of dual-sized silica particles of 600 and 800 nm in acidic silica sol, showed hydrophilicity with water contact angle of 45° before heat treatment due to the presence of-OH groups from acidic sol. After heat treatment at 250°C for 2 h in atmospheric ambience, the-OH groups reacted to form cross-linked Si-O-Si resulting in superhydrophobicity of the coating with water contact angle of 147°. In this work, silica based superhydrophobic coating was fabricated by adjusting the ratios of the dual-sized silica particles without carrying out any secondary step such as chemical modification or fluorination process on the coating.

BACKGROUND The use of biodegradable polymer drug-eluting stents (BP-DES) has been proven to minimize restenosis and stent thrombosis. The current post-marketing monitoring was observed at the 5-year clinical outcomes of individuals who had been treated with FlexyRap ® DES in the real world. AIM To assess the safety and effectiveness of FlexyRap ® DES at the 5-year follow-up in real-world settings. METHODS Findings from a retrospective, multi-center, observational, post-market clinical follow-up study of patients treated with FlexyRap ® DES for de novo coronary artery disease (CAD) were reported. During the 12-mo follow-up, the primary endpoint was target lesion failure, which was defined as the composite of cardiovascular death, target vessel myocardial infarction (TV-MI), and clinically driven target lesion revascularization. RESULTS The data of 500 patients received with FlexyRap ® DES was obtained at the completion of the surveillance timeline of 5-year. After the implantation of FlexyRap ® DES, the device success rate was 100%. Adverse events that led to major bleeding, permanent disability, or death were not experienced in the patients. The major adverse cardiac event rate at 12-mo, 3-year, and 5-year follow-up was 1 (0.2%), 0 (0%), and 1 (0.2%) respectively with 0 (0%) cardiovascular death, 2 (0.4%) TV-MI, and 0 (0%) TLR compositely. Furthermore, late stent thrombosis was found in 2 (0.4%) patients at the follow-up of 12-mo, very late stent thrombosis was observed in 2 patients (0.4%) at 3-year follow-up. CONCLUSION FlexyRap ® DES was proved to be safe and efficacious in real-world patients with de novo CAD, indicating a lowered rate of cardiac events and stent thrombosis at 5-year follow-up.

Abstract

No abstract